In particular, compared to the conventional serum-based markers (e.g., serum creatinine, blood urea nitrogen, and estimated glomerular filtration rate), recently identified proteomic biomarkers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are known to enhance sensitivity and specificity, particularly in early stages of kidney diseases where the conventional markers show no detectable changes [3,4]. The gene discussed is LCN2; the disease is kidney disorder.